TrkB.T1 Antibody Composition for Pan-Cancer Isoform Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions and methods that can reliably detect various cancer types with a generalized cancer marker, as existing markers are limited in their ability to signify a broad range of cancers effectively.
Innovation Solution
Development of antibodies and antibody-binding derivatives that specifically bind to the C-terminal domain of the tropomyosin receptor kinase B (TrkB) isoform, particularly TrkB.T1, which is highly conserved across species and can be used to detect elevated levels of TrkB isoforms in cancer tissues, including solid and non-solid tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing cancer markers are used, then detection of specific cancer types is achieved, but the ability to detect a broad range of cancers is limited
Solution Approach 1:
The patent applies universality by developing an antibody (anti-TrkB.T1) that detects a marker (TrkB.T1 isoform) expressed across multiple cancer types including glioblastoma, medulloblastoma, and other solid tumors. This single antibody provides pan-cancer detection capability, making the detection system universal across different cancer types rather than requiring separate markers for each cancer type.
2Measurement precision
If multiple cancer-specific markers are developed, then detection precision for specific cancer types improves, but the complexity of the detection system increases
Solution Approach 1:
The patent employs universality by using a single antibody that targets the TrkB.T1 isoform, which serves as a common marker across multiple cancer types. This approach allows one detection system to identify various cancers without requiring multiple cancer-specific antibodies, thereby maintaining measurement precision while reducing system complexity.
3Reliability
If early cancer detection is achieved through sensitive markers, then treatment success is maximized, but the challenge of identifying reliable pan-cancer markers remains
Solution Approach 1:
The patent resolves this contradiction by identifying and targeting the TrkB.T1 isoform, which demonstrates both high reliability as a cancer marker and broad adaptability across multiple cancer types. The anti-TrkB.T1 antibody reliably detects this isoform in various cancers including glioblastoma and medulloblastoma, achieving both detection reliability and cross-cancer applicability simultaneously.
Data Source
AI summary
In some aspects, the disclosure provides antibody-based reagents that specifically bind a tropomyosin receptor kinase B (TrkB) isoform that is associated with cancers. In some embodiments, the isoform is TrkB.T1. In some embodiments, the antibody or antibody derivative specifically binds a polypeptide comprising, consisting essentially of, or consisting of the sequence FVLFHKIPLDG (SEQ ID NO:1), or a sequence with at least 80% sequence identity thereto. In other aspects, the disclosure provides methods of producing the antibody or antibody derivative, related hybridomas, and methods of detecting and treating cancers incorporating use of the disclosed antibody reagents.